[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Ueda Y, Yamagishi T, Samata K, Hirayama N, Aozuka Y, Tanaka M, Nakaike S, Saiki I: Antitumor effects of synthetic VEGF-receptor binding antagonist, VGA1155. Anticancer Res; 2005 Nov-Dec;25(6B):3973-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, VEGF and its receptors are considered to be primary targets for antiangiogenic strategy during cancer chemotherapy.
  • VGA1155 suppressed the growth of human lung, breast, colon and epidermoid cancers (LC-6, HT29, MX-1, Col-1 and A431) in the nude mouse xenograft model, and pulmonary metastasis of melanoma in the spontaneous metastasis model.
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Breast Neoplasms / blood supply. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / blood supply. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cell Growth Processes / drug effects. Colonic Neoplasms / blood supply. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Humans. Lung Neoplasms / blood supply. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Melanoma, Experimental / blood supply. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. Neovascularization, Pathologic / drug therapy. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309186.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoates; 0 / VGA1155; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


2. Tejeda M, Gaal D, Hullán L, Csuka O, Schwab R, Szokoloczi O, Kéri GY: Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models. Anticancer Res; 2008 Sep-Oct;28(5A):2769-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models.
  • TT-232 had previously been shown to inhibit the proliferation of a large number of cancer cell lines in vitro and reduce the size of different tumors in animal models in vivo.
  • MATERIALS AND METHODS: The therapeutic efficacy of TT-232 was evaluated in different long-term administration routes: the traditional injection (i.p. or s.c.) versus infusion treatment via s.c. - or i.v.
  • -inserted Alzet osmotic minipump, and on different types of transplantable rodent (S-180 sarcoma, P-388sc lymphoid leukemia, Colon-26 adenocarcinoma, MXT breast carcinoma, B-16 melanoma) and human tumor models (HT-18 lymphoid melanoma, T-47/D breast carcinoma, A-431 epidermoid carcinoma).
  • This dose is equivalent to 0.6 dg/day by infusion therapy.
  • RESULTS: In our experiments, the best results were achieved when TT-232 was applied as an infused treatment.
  • In the S-180 sarcoma and P-388sc lymphoid leukemia rodent tumor models the infusion treatment with TT-232 resulted in 61%-100% tumor growth inhibition and in 20%-60% of the mice being long-term and tumor-free survivors.
  • In the aggressive Colon-26 adenocarcinoma and MXT breast carcinoma models, the infusion treatment resulted in 52%-75% tumor growth inhibition.
  • In the B-16 melanoma model, the infusion treatments resulted in 47% -63% growth inhibition.
  • The tumor growth inhibitory effect of infusion treatment with TT-232 on HT-18 human lymphoid melanoma tumor proved to be significant, resulting in 69%-79% decreases in tumor volume.
  • In the T-47/D human breast carcinoma, the infusion treatment resulted in 48%-53% tumor growth inhibition.
  • The tumor growth inhibitory effect of infusion treatment on A-431 human epidermoid carcinoma tumor resulted in 70%-74% decreases in tumor volume.
  • In our study, the route of infusion was shown to increase drug efficacy relative to conventional delivery methods (injection).
  • The results obtained from this study suggest that TT-232 is a promising new antitumor agent in cancer chemotherapy and a good candidate for delivery by continuous (infusion) therapy.
  • [MeSH-major] Neoplasms, Experimental / drug therapy. Peptides, Cyclic / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035308.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Peptides, Cyclic; 0 / TT2-32; 51110-01-1 / Somatostatin
  •  go-up   go-down


3. Sato H, Kuroda M, Maruta M, Maeda K, Koide Y: Mucoepidermoid carcinoma of the ascending colon: report of a case. Surg Today; 2002;32(11):1004-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the ascending colon: report of a case.
  • Mucoepidermoid carcinoma of the gastrointestinal tract is a rare entity.
  • The present case is the first report of mucoepidermoid carcinoma in the large bowel.
  • An ulcerating tumor was thus identified in the ascending colon.
  • The tumor consisted of PAS-positive mucin-producing cells, epidermoid cells, and intermediate cells.
  • No differentiated squamous cell carcinoma cells were identified in any part of the tumor.
  • The tumor was diagnosed as a mucoepidermoid carcinoma of the ascending colon.
  • Unfortunately, despite chemotherapy, the patient developed liver metastases and died of liver failure 10 months postoperatively.
  • [MeSH-major] Carcinoma, Mucoepidermoid / surgery. Colonic Neoplasms / surgery

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12444441.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Copur S, Ledakis P, Novinski D, Mleczko KL, Frankforter S, Bolton M, Fruehling RM, VanWie E, Norvell M, Muhvic J: Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy. Clin Colorectal Cancer; 2001 May;1(1):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy.
  • Primary squamous cell colorectal carcinomas are uncommon, and their characteristics are not well known.
  • The most commonly reported anatomic locations are the rectum and the proximal colon.
  • Clinical features and common diagnostic methods do not easily differentiate squamous cell colorectal carcinomas from adenocarcinomas.
  • Because of their extremely rare occurrence, it is difficult to study their natural course, clinical behavior, and response to therapy.
  • This report presents the case of a pure squamous cell colorectal cancer and provides a brief review of the literature, which includes 60 previously published cases.
  • The case of a patient with T3N2M0 primary squamous cell carcinoma of the rectosigmoid colon, which was initially treated with abdominoperineal resection followed by adjuvant chemotherapy and radiation, is presented.
  • During the follow-up, an elevated squamous cell carcinoma antigen (SCC Ag) level led to restaging computed tomography scans, which confirmed recurrent metastatic disease in the liver.
  • Response to chemotherapy with a decrease in tumor size correlated with a decrease in the serum SCC Ag level.
  • Although SCC Ag has been used as a tumor marker for squamous cell cancers of the lung, head and neck, uterine cervix, and esophagus, this is the first reported case of a squamous cell colon carcinoma presenting with an elevated SCC Ag at the time of recurrence.
  • In addition, this patient showed an objective partial response to combination chemotherapy, with a decrease in the serum level of this tumor marker.
  • [MeSH-major] Antigens, Neoplasm / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / drug therapy. Colonic Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Serpins
  • [MeSH-minor] Cisplatin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445380.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Serpins; 0 / squamous cell carcinoma-related antigen; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Voigt W, Pickan V, Pfeiffer C, Mueller T, Simon H, Arnold D: Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use. Onkologie; 2005 Oct;28(10):482-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.
  • BACKGROUND: Preclinical studies have suggested antitumor activity of an epidermal growth factor (EGF)-receptor targeted therapy with selective tyrosine kinase inhibitors alone or in combination with conventional cytostatic drugs.
  • However, in non-small cell lung cancer (NSCLC), addition of ZD1839 (Iressa) to combination chemotherapy did not improve the therapeutic outcome.
  • Thus, further work is necessary to define factors predicting outcome of combination therapy.
  • MATERIALS AND METHODS: In the present study, the activity of ZD1839 alone or in combination with oxaliplatin (Eloxatin) was evaluated in 12 human cancer cell lines including colon, testicular, anaplastic thyroid and epidermoid carcinoma cells.
  • RESULTS: The EGF-receptor protein was overexpressed in line A431 (epidermoid carcinoma) and near the minimum detection limit in all other cell lines.
  • The single agent activity of ZD1839 was highest in cell line A431.
  • In the other cell lines, it was lower and appeared to be independent of EGF-receptor expression levels.
  • Combined exposure to oxaliplatin and ZD1839 (IC30) resulted in significant synergy in 4 out of 6 colorectal cancer (CRC) cell lines and significant antagonism in 4 out of 6 non-colorectal cancer cell lines.
  • Continuous exposure to ZD1839 (IC30) induced a marked G1-phase arrest and dephosphorylation of EGF-receptor in A431, whereas no significant cell cycle perturbation could be detected in the low-expression cell lines.
  • Other factors than cell cycle perturbation seem to determine the mode of drug interaction between oxaliplatin and ZD1839.
  • CONCLUSION: Based on RAA, the single agent activity of ZD1839 in the investigated cell line panel appeared to be low.
  • Combined exposure to ZD1839 and oxaliplatin exerted synergy in colorectal cancer cell lines, warranting further evaluation in this type of cancer.
  • However, based on the observed antagonism in non-colorectal cancer cell lines, combined treatment with ZD1839 and oxaliplatin is not recommended for other types of cancer.
  • Further research is necessary to identify factors which determine the nature of drug interaction in different tumor types including CRC and lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasms / metabolism. Neoplasms / pathology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Humans. Lethal Dose 50. Organoplatinum Compounds / administration & dosage. Quinazolines / administration & dosage

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160394.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Quinazolines; 04ZR38536J / oxaliplatin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


6. Dubin M, Fernandez Villamil SH, Stoppani AO: [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use]. Medicina (B Aires); 2001;61(3):343-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use].
  • These enzymes are essential for maintaining DNA structure. beta-Lap inhibited growth of a large variety of tumor cells including epidermoid laringeal cancer, prostate, colon, ovary and breast cancer and also different types of leukemia cells.
  • Advances in knowledge of apoptosis ("programmed cell death") and necrosis provided useful information for understanding the mechanism of beta-lap cytotoxicity.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Naphthoquinones / pharmacology. Neoplasms / drug therapy. Poly(ADP-ribose) Polymerases / metabolism. Reactive Oxygen Species / physiology
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / enzymology. Humans. Sarcoma, Yoshida / drug therapy. Sarcoma, Yoshida / enzymology. Topoisomerase I Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11474885.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Naphthoquinones; 0 / Reactive Oxygen Species; 0 / Topoisomerase I Inhibitors; 4707-32-8 / beta-lapachone; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 58
  •  go-up   go-down


7. Mathonnet M, Fermeaux V: [Colon cancer in pregnancy]. J Chir (Paris); 2003 Sep;140(4):221-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colon cancer in pregnancy].
  • Colon cancers arise only rarely in the course of a pregnancy.
  • Yet colon obstruction, perforation and metastatic spread seem to occur more frequently in this setting than with the average colon cancer.
  • No case of epidermoid (squamous cell) cancer of the colon has been previously described in a pregnant woman.
  • This conjunction has a catastrophic prognosis: the diagnosis of colon tumor is delayed since symptoms are masked by the pregnancy, and epidermoid colon cancer is a particularly aggressive lesion.
  • A major sub-diaphragmatic surgical procedure can be performed with reasonable safety to mother and fetus.
  • Neo-adjuvant chemotherapy can be administered although the risks to the fetus are not well known.
  • During the first trimester, a therapeutic abortion can be proposed to optimise the treatment of the mother.
  • During the second and third trimesters, treatment of the mother exposes the fetus to the risk of malformations or premature delivery; delay in maternal treatment in hopes of prolonging the pregnancy in order to obtain a viable neonate diminish the chances of maternal survival.
  • [MeSH-major] Carcinoma, Squamous Cell. Colonic Neoplasms. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cesarean Section. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Diseases in Twins. Down Syndrome. Fatal Outcome. Female. Fetal Death. Fluorouracil / administration & dosage. Humans. Intestinal Perforation / etiology. Leucovorin / administration & dosage. Liver Neoplasms / secondary. Male. Organoplatinum Compounds / administration & dosage. Pregnancy. Pregnancy, Multiple

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13679771.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FOLFOX2-3 regimen
  • [Number-of-references] 20
  •  go-up   go-down


8. Schoenlein PV, Barrett JT, Kulharya A, Dohn MR, Sanchez A, Hou DY, McCoy J: Radiation therapy depletes extrachromosomally amplified drug resistance genes and oncogenes from tumor cells via micronuclear capture of episomes and double minute chromosomes. Int J Radiat Oncol Biol Phys; 2003 Mar 15;55(4):1051-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy depletes extrachromosomally amplified drug resistance genes and oncogenes from tumor cells via micronuclear capture of episomes and double minute chromosomes.
  • PURPOSE: To determine if clinically relevant doses of ionizing radiation are capable of inducing extrachromosomal DNA loss in transformed human cell lines.
  • MATERIALS AND METHODS: The multidrug-resistant (MDR) human epidermoid KB-C1 cell line and the human neuroendocrine colon carcinoma line COLO320, which contain extrachromosomally amplified MDR1 drug resistance genes and MYCC oncogenes, were irradiated with 2 Gy fractions up to a total dose of 28 Gy.
  • To track the fate of extrachromosomally amplified genes, cells surviving radiation therapy and unirradiated control cells were analyzed by fluorescent in situ hybridization of chromosomes using MDR1 and MYCC-specific cosmid DNA probes.
  • [MeSH-major] Drug Resistance, Neoplasm / radiation effects. Gene Amplification. Gene Deletion. Genes, MDR / radiation effects. Genes, myc / radiation effects. P-Glycoprotein / analysis. Proto-Oncogene Proteins c-myc / analysis
  • [MeSH-minor] Cell Line, Transformed / drug effects. Cell Line, Transformed / radiation effects. Dose Fractionation. Dose-Response Relationship, Radiation. Flow Cytometry. Humans. Micronucleus Tests. Radiation Tolerance / drug effects. Radiation Tolerance / genetics. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / radiation effects. Tumor Stem Cell Assay

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12605985.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


9. Gouazé V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE, Cabot MC: Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther; 2004 May;3(5):633-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.
  • Resistance to natural product chemotherapy drugs is a major obstacle to successful cancer treatment.
  • This type of resistance is often acquired in response to drug exposure; however, the mechanisms of this adverse reaction are complex and elusive.
  • Here, we have studied acquired resistance to Adriamycin, Vinca alkaloids, and etoposide in MCF-7 breast cancer cells, KB-3-1 epidermoid carcinoma cells, and other cancer cell lines to determine if there is an association between expression of glucosylceramide synthase, the enzyme catalyzing ceramide glycosylation to glucosylceramide, and the multidrug-resistant (MDR) phenotype.
  • This work shows that glucosylceramide levels increase concomitantly with increased drug resistance in the KB-3-1 vinblastine-resistant sublines KB-V.01, KB-V.1, and KB-V1 (listed in order of increasing MDR).
  • In breast cancer, detailed analysis of MCF-7 wild-type and MCF-7-AdrR cells (Adriamycin-resistant) demonstrated enhanced glucosylceramide synthase message and protein, P-gp message and protein, and high levels of glucosylceramide in resistant cells.
  • Similar results were seen in vincristine-resistant leukemia, etoposide-resistant melanoma, and Adriamycin-resistant colon cancer cell lines.
  • Cell-free glucosylceramide synthase activity was higher in lysates obtained from drug-resistant cells.
  • We conclude that selection pressure for resistance to natural product chemotherapy drugs selects for enhanced ceramide metabolism through glucosylceramide synthase in addition to enhanced P-gp expression.
  • A possible connection between glucosylceramide synthase and P-gp in drug resistance biology is suggested.
  • [MeSH-major] Biological Factors / pharmacology. Drug Resistance, Neoplasm / physiology. Glucosyltransferases / metabolism. P-Glycoprotein / metabolism
  • [MeSH-minor] Cell Line, Tumor. Doxorubicin / pharmacology. Etoposide / pharmacology. Glucosylceramides / metabolism. Humans. RNA, Messenger / genetics. RNA, Messenger / metabolism. Vinblastine / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15141021.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA95339
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biological Factors; 0 / Glucosylceramides; 0 / P-Glycoprotein; 0 / RNA, Messenger; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; EC 2.4.1.- / Glucosyltransferases; EC 2.4.1.80 / ceramide glucosyltransferase
  •  go-up   go-down


10. Azevedo CR, Cezana L, Moraes ES, Begnami MD, Paiva Júnior TF, Dettino AL, Fanelli MF: Synchronous thyroid and colon metastases from epidermoid carcinoma of the lung: case report. Sao Paulo Med J; 2010 Dec;128(6):371-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous thyroid and colon metastases from epidermoid carcinoma of the lung: case report.
  • CONTEXT: Non-small cell lung cancer (NSCLC) progresses to distant metastases in most cases.
  • CASE REPORT: We describe a case of squamous cell carcinoma in the lungs, with metastases in the colon and thyroid, in a 66-year-old female patient.
  • The lesion was unresectable and chemotherapy was started.
  • Biopsy and immunohistochemical analysis on the polyp showed that it was compatible with squamous cell carcinoma of pulmonary origin.
  • A aspiration biopsy and cellblock immunohistochemistry confirmed the squamous cell carcinoma of pulmonary origin.
  • After third-line chemotherapy, the patient progressed with acute obstructive abdomen due to a retroperitoneal mass.
  • Metastases to the thyroid and colon are rarely reported in cases of epidermoid carcinoma of the lungs.
  • Gastrointestinal involvement in pulmonary metastases may affect the stomach, small intestine and colon, and cases of bleeding and perforation have already been reported.
  • We did not find any previous reports in the literature, on lung cancer with metastases concomitantly in the colon and thyroid, in a single patient.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Colonic Neoplasms / secondary. Lung Neoplasms / pathology. Thyroid Neoplasms / secondary

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308162.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


11. Li Q, Gao C, Juzi JT, Hao X: Analysis of 82 cases of retroperitoneal schwannoma. ANZ J Surg; 2007 Apr;77(4):237-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of the study was to improve the diagnosis and treatment of retroperitoneal schwannoma by analysing clinical manifestations and postoperative course of this rare disease.
  • Only in 13 patients (15.9%) a correct preoperative diagnosis was made by either ultrasound-guided biopsy, computed tomography scanning or magnetic resonance imaging.
  • All patients received operative therapy.
  • Two patients (2.4%) had multiple schwannomas and two others had a simultaneous malignancy (adenocarcinoma of the ascending colon and squamous-cell carcinoma of the lung, respectively).
  • However, with the preoperative assessment of ultrasound-guided fine-needle aspiration, computed tomography and magnetic resonance imaging, the accuracy of diagnosis could definitely be improved.
  • Treatment depends solely on surgery.
  • Malignant schwannomas are insensitive to chemotherapy and radiation, resulting in poor prognosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388825.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


12. Ghouti L, Houvenaeghel G, Moutardier V, Giovannini M, Magnin V, Lelong B, Bardou VJ, Delpero JR: Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum; 2005 Jan;48(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer.
  • PURPOSE: Radiotherapy alone or with combined chemotherapy is the first therapeutic option for epidermoid carcinoma of the anal canal.
  • Failure of this conservative treatment may benefit of salvage abdominoperineal resection.
  • METHODS: Medical charts of 36 patients (median age, 57.9 years) who underwent salvage abdominoperineal resection after failure of conservative treatment between 1987 and 2002 were reviewed retrospectively.
  • CONCLUSIONS: Despite high incidence of perineal morbidity, salvage abdominoperineal resection for epidermoid carcinomas of the anal canal has a high long-term survival rate.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Perineum / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Morbidity. Retrospective Studies. Salvage Therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690652.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Blumetti J, Bastawrous AL: Epidermoid cancers of the anal canal: current treatment. Clin Colon Rectal Surg; 2009 May;22(2):77-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid cancers of the anal canal: current treatment.
  • Epidermoid carcinoma of the anal canal is an uncommon disease, but has increased in incidence with the HIV epidemic.
  • Prior to the 1970s, treatment consisted of radical surgery with abdominoperineal resection.
  • Norman Nigro, this has shifted to a nonsurgical approach, with primary treatment consisting of multimodality therapy with radiation and chemotherapy.
  • This review provides an overview of the historical, current, and future treatments of epidermoid anal canal malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2004 Nov 27;329(7477):1272-6 [15564260.001]
  • [Cites] ANZ J Surg. 2004 Jul;74(7):541-6 [15230786.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):478-83 [17103253.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3669-71 [18519948.001]
  • [Cites] Surg Oncol. 1994 Jun;3(3):135-46 [7952397.001]
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):890-4 [18178364.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):886-91 [11485523.001]
  • [Cites] Am J Surg. 1976 Mar;131(3):275-80 [1259098.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1305-9 [15484343.001]
  • [Cites] Br J Surg. 2005 May;92(5):605-14 [15739215.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1176-81 [15906137.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Colorectal Dis. 2006 Feb;8(2):124-9 [16412072.001]
  • [Cites] Am J Surg. 1991 Dec;162(6):580-4 [1670229.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):2-9 [18030528.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] Dis Colon Rectum. 2008 Feb;51(2):147-53 [18180997.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26 [18472366.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):43-8 [6691550.001]
  • [Cites] Cancer. 1983 May 15;51(10):1826-9 [6831348.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):709-11 [8348857.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 1981 Mar-Apr;24(2):73-5 [7215078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1259-73 [12873670.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]
  • (PMID = 20436831.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780240
  • [Keywords] NOTNLM ; Anal canal malignancy / Nigro protocol / chemoradiation / epidermoid carcinoma
  •  go-up   go-down


14. Rooney S, Ryan MF: Effects of alpha-hederin and thymoquinone, constituents of Nigella sativa, on human cancer cell lines. Anticancer Res; 2005 May-Jun;25(3B):2199-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of alpha-hederin and thymoquinone, constituents of Nigella sativa, on human cancer cell lines.
  • The separate effects of alpha-hederin and thymoquinone, the two principal bioactive constituents of Nigella sativa, on four human cancer cell lines [A549 (lung carcinoma), HEp-2 (larynx epidermoid carcinoma), HT-29 (colon adenocarcinoma) and MIA PaCa-2 (pancreas carcinoma)] were investigated.
  • Alpha-hederin was also examined as a pro-drug.
  • Alpha-hederin and thymoquinone separately induced a dose- and time-dependent effect on the cell lines tested.
  • HEp-2 cells were the most sensitive, exhibiting apoptosis with a higher incidence following thymoquinone treatment.
  • Pre-treatment of cells with alpha-hederin, followed by thymoquinone or cisplatin, did not enhance the cytotoxicity or apoptosis induced by either drug.
  • [MeSH-major] Benzoquinones / pharmacology. Drugs, Chinese Herbal / pharmacology. Neoplasms / drug therapy. Oleanolic Acid / analogs & derivatives. Saponins / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Apoptosis / drug effects. Cell Line, Tumor. Colonic Neoplasms / drug therapy. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. HT29 Cells. Humans. Inhibitory Concentration 50. Laryngeal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Necrosis. Nigella sativa / chemistry. Pancreatic Neoplasms / drug therapy. Prodrugs / pharmacology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158964.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Drugs, Chinese Herbal; 0 / Prodrugs; 0 / Saponins; 27013-91-8 / alpha-hederin; 490-91-5 / thymoquinone; 6SMK8R7TGJ / Oleanolic Acid
  •  go-up   go-down


15. van der Wal BC, Cleffken BI, Gulec B, Kaufman HS, Choti MA: Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy. J Gastrointest Surg; 2001 Jul-Aug;5(4):383-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy.
  • Combined chemotherapy and radiation therapy is the standard treatment for epidermoid carcinoma of the anal canal.
  • The aim of this study was to review our experience with abdominoperineal resection following failure of chemoradiation therapy for epidermoid carcinoma of the anus.
  • Between 1980 and 1998, 17 patients underwent salvage abdominoperineal resection following failure of chemoradiation therapy.
  • The median follow-up time for the patients operated on with curative intent was 53 months.
  • Selected patients with recurrent or persistent anal carcinoma following chemoradiation therapy can be offered salvage abdominoperineal resection.
  • Prolonged survival can be achieved in some patients following salvage resection for epidermoid carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / epidemiology. Reconstructive Surgical Procedures. Salvage Therapy. Surgical Flaps. Survival Analysis. Time Factors. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):574-7; discussion 577-8 [1587176.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1525-9 [9769399.001]
  • [Cites] Dis Colon Rectum. 1987 May;30(5):324-33 [3568920.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):478-85 [1589984.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Tumori. 1998 Mar-Apr;84(2):247-9 [9620252.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):525-9 [3942984.001]
  • [Cites] Acta Oncol. 1993;32(1):33-5 [8466762.001]
  • [Cites] Ann Surg Oncol. 1994 Mar;1(2):105-10 [7834434.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1099-105 [9392550.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):40-9 [8024357.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • (PMID = 11985979.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Jiang X, Zhen Y: Cinnamamide, an antitumor agent with low cytotoxicity acting on matrix metalloproteinase. Anticancer Drugs; 2000 Jan;11(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By the MTT assay the IC50 (50% inhibitory concentration) values of CNM on cell proliferation ranged from 1.29 to 1.94 mM in human oral epidermoid carcinoma KB cells, human hepatoma BEL-7402 cells and human fibrosarcoma HT-1080 cells.
  • At the dose of 100 mg/kg, CNM inhibited the growth of colon 26 carcinoma by 39.0% and that of Lewis lung carcinoma by 53.9%.
  • In the Lewis lung carcinoma model, CNM at the dose of 100 mg/kg (i.p.) also reduced the lung metastasis by 59.1%.
  • These results indicate that CNM is an antitumor agent with low cytotoxicity acting on MMP and may serve as a lead compound in the development of antitumor drugs.
  • [MeSH-minor] Animals. Cell Division / drug effects. Disease Models, Animal. Humans. KB Cells. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Neoplasm Transplantation. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / secondary. Tumor Cells, Cultured

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10757563.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cinnamates; 0 / cinnamamide; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


17. Anagnostopoulos G, Sakorafas GH, Kostopoulos P, Grigoriadis K, Pavlakis G, Margantinis G, Vugiouklakis D, Arvanitidis D: Squamous cell carcinoma of the rectum: a case report and review of the literature. Eur J Cancer Care (Engl); 2005 Mar;14(1):70-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the rectum: a case report and review of the literature.
  • Squamous cell carcinoma of the colon and rectum are extremely rare neoplasms.
  • Surgery is the most effective therapy, and adjuvant chemotherapy and radiotherapy should be considered, especially for node-positive patients.
  • We present a patient with squamous cell carcinoma of the middle rectum who underwent abdominoperineal resection and postoperative adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell. Rectal Neoplasms
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant / methods. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer Care (Engl). 2005 Dec;14(5):465 [16274470.001]
  • (PMID = 15698388.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


18. de Parades V, Bauer P, Benbunan JL, Bouillet T, Cottu PH, Cuenod CA, Durdux C, Fléjou JF, Atienza P: [Initial pretherapeutic assessment of anal epidermoid carcinoma]. Gastroenterol Clin Biol; 2007 Feb;31(2):157-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Initial pretherapeutic assessment of anal epidermoid carcinoma].
  • Anal epidermoid carcinoma is a rare malignant tumor, comprising less than 5% of all carcinomas of the colon, rectum, and anus.
  • The primary therapy now includes radiotherapy, often in combination with chemotherapy.
  • Therapeutic indications are based on locoregional staging, the presence of visceral metastases and an evaluation of the medical history.
  • In addition, magnetic resonance imaging, positron emission tomography scanning and inguinal sentinel lymph node procedure should play a role in a more selective approach in patients with anal carcinoma.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347624.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 96
  •  go-up   go-down


19. Hanessian S, Saavedra OM, Xie F, Amboldi N, Battistini C: Design and synthesis of functionalized glycomers as non-peptidic ligands for SH2 binding and as inhibitors of A-431 human epidermoid and HT-29 colon carcinoma cell lines. Bioorg Med Chem Lett; 2000 Mar 6;10(5):439-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design and synthesis of functionalized glycomers as non-peptidic ligands for SH2 binding and as inhibitors of A-431 human epidermoid and HT-29 colon carcinoma cell lines.
  • A set of O-substituted aryl beta-D-glucopyranosides were prepared and found to have inhibitory activity on the growth of two carcinoma cell lines.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Glucosides / chemical synthesis. src Homology Domains / drug effects
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. HT29 Cells. Humans. Ligands. Molecular Conformation. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10743943.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucosides; 0 / Ligands
  •  go-up   go-down


20. Whelan LC, Ryan MF: Effects of the polyacetylene capillin on human tumour cell lines. Anticancer Res; 2004 Jul-Aug;24(4):2281-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the polyacetylene capillin on human tumour cell lines.
  • We investigated the effects of capillin, a constituent of Artemisia monosperma, on four human tumour cell lines: colon carcinoma H729, pancreatic carcinoma MIA PaCa-2, epidermoid carcinoma of the larynx HEp-2 and lung carcinoma A549.
  • Changes in cell proliferation, membrane permeability, macromolecular synthesis, glutathione (GSH), cell cycle and programmed cell death were evaluated.
  • Capillin (1microM-10microM) inhibited cell proliferation and decreased macromolecular synthesis simultaneously, in a dose- and time-dependent manner.
  • Co-incubation with L-buthionine sulfoximine (L-BSO) augmented the efficacy of capillin.
  • Capillin modulated GSH levels, accumulated cells in the S+G2/M-phase of the cell cycle and induced cell death and DNA fragmentation, as indicated by flow cytometry, fluorescence microscopy and DNA fragmentation assay.
  • These findings suggest that capillin has cytotoxic activity and can induce apoptosis in human tumour cell lines.
  • [MeSH-minor] Apoptosis / drug effects. Buthionine Sulfoximine / pharmacology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Cycle / drug effects. Cell Division / drug effects. Cell Line, Tumor. Colonic Neoplasms / drug therapy. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. DNA, Neoplasm / antagonists & inhibitors. DNA, Neoplasm / biosynthesis. Diynes. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Glutathione / metabolism. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / metabolism. Laryngeal Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Proteins / biosynthesis. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Plant Extracts / pharmacology. RNA, Neoplasm / antagonists & inhibitors. RNA, Neoplasm / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15330173.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Alkynes; 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Neoplasm; 0 / Diynes; 0 / Neoplasm Proteins; 0 / Plant Extracts; 0 / RNA, Neoplasm; 495-74-9 / capillin; 5072-26-4 / Buthionine Sulfoximine; GAN16C9B8O / Glutathione
  •  go-up   go-down


21. Cao S, Durrani FA, Rustum YM: Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res; 2004 Apr 1;10(7):2561-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
  • PURPOSE: Studies were carried out in athymic nude mice bearing human squamous cell carcinoma of the head and neck (FaDu and A253) and colon carcinoma (HCT-8 and HT-29) xenografts to evaluate the potential role of selenium-containing compounds as selective modulators of the toxicity and antitumor activity of selected anticancer drugs with particular emphasis on irinotecan, a topoisomerase I poison.
  • EXPERIMENTAL DESIGN: Antitumor activity and toxicity were evaluated using nontoxic doses (0.2 mg/mouse/day) and schedule (14-28 days) of the selenium-containing compounds, 5-methylselenocysteine and seleno-L-methionine, administered orally to nude mice daily for 7 days before i.v. administration of anticancer drugs, with continued selenium treatment for 7-21 days, depending on anticancer drugs under evaluation.
  • Several doses of anticancer drugs were used, including the maximum tolerated dose (MTD) and toxic doses.
  • Administration of these higher doses was possible due to selective protection of normal tissues by selenium.
  • Thus, the use of selenium as selective modulator of the therapeutic efficacy of anticancer drugs is new and novel.
  • CONCLUSIONS: We demonstrated that selenium is a highly effective modulator of the therapeutic efficacy and selectivity of anticancer drugs in nude mice bearing human tumor xenografts of colon carcinoma and squamous cell carcinoma of the head and neck.
  • [MeSH-major] Camptothecin / analogs & derivatives. Cysteine / analogs & derivatives. Neoplasms / drug therapy. Selenium / therapeutic use
  • [MeSH-minor] Administration, Oral. Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Cell Line, Tumor. Colonic Neoplasms / metabolism. Dose-Response Relationship, Drug. Drug Synergism. Female. Humans. Maximum Tolerated Dose. Mice. Mice, Nude. Neoplasm Transplantation. Organoselenium Compounds / pharmacology. Radiation-Sensitizing Agents / pharmacology. Selenocysteine / analogs & derivatives. Selenomethionine / pharmacology. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SELENIUM METHIONINE .
  • Hazardous Substances Data Bank. SELENO-(DL)-CYSTEINE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15073137.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / R01 CA76951
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoselenium Compounds; 0 / Radiation-Sensitizing Agents; 0CH9049VIS / Selenocysteine; 7673326042 / irinotecan; 964MRK2PEL / Selenomethionine; H6241UJ22B / Selenium; K848JZ4886 / Cysteine; TWK220499Z / selenomethylselenocysteine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement